PCIG
ALLO icon

Partners Capital Investment Group’s Allogene Therapeutics ALLO Stock Holding History

Partners Capital Investment Group’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$336K Hold
161,597
– – 0.01% 157
2026
Q1 		$394K Hold
161,597
– – 0.01% 140
2025
Q4 		$221K Hold
161,597
– – 0.01% 157
2025
Q3 		$200K Hold
161,597
– – 0.01% 160
2025
Q2 		$183K Sell
161,597
-93,248
-37% -$124K 0.01% 158
2025
Q1 		$372K Buy
254,845
+161,597
+173% +$305K 0.01% 159
2024
Q4 		$199K Sell
93,248
-161,597
-63% -$399K 0.01% 124
2024
Q3 		$714K Sell
254,845
-200,000
-44% -$533K 0.01% 144
2024
Q2 		$1.07M Buy
454,845
+361,597
+388% +$1.07M 0.02% 143
2024
Q1 		$417K Sell
93,248
-361,597
-79% -$1.51M 0.01% 136
2023
Q4 		$1.46M Hold
454,845
– – 0.03% 129
2023
Q3 		$1.44M Hold
454,845
– – 0.03% 129
2023
Q2 		$2.26M Buy
454,845
+361,597
+388% +$1.96M 0.05% 125
2023
Q1 		$461K Hold
93,248
– – 0.02% 111
2022
Q4 		$587K Hold
93,248
– – 0.03% 112
2022
Q3 		$1.01M Hold
93,248
– – 0.06% 105
2022
Q2 		$1.06M Hold
93,248
– – 0.07% 93
2022
Q1 		$849K Hold
93,248
– – 0.04% 101
2021
Q4 		$1.39M Hold
93,248
– – 0.06% 97
2021
Q3 		$2.4M Hold
93,248
– – 0.11% 86
2021
Q2 		$2.43M Sell
93,248
-12,506
-12% -$357K 0.11% 100
2021
Q1 		$3.73M Sell
105,754
-155,778
-60% -$5.25M 0.16% 85
2020
Q4 		$6.6M Buy
261,532
+124,513
+91% +$4.06M 0.19% 75
2020
Q3 		$5.17M Sell
137,019
-11,645
-8% -$439K 0.32% 61
2020
Q2 		$6.37M Sell
148,664
-18,326
-11% -$663K 0.31% 59
2020
Q1 		$3.25M Sell
166,990
-16,760
-9% -$399K 0.22% 65
2019
Q4 		$4.77M Buy
+183,750
New +$5.06M 0.36% 59

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Partners Capital Investment Group's ALLO Position: Q2 2026 in Review

Partners Capital Investment Group held its Allogene Therapeutics (ALLO) position steady in Q2 2026 at 161,597 shares worth $336K. The position accounts for 0.01% of the portfolio, ranked #157.

Partners Capital Investment Group first reported a position in ALLO in Q4 2019 and has held it in 27 quarters since. The position peaked at $6.6M in Q4 2020. 210 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Partners Capital Investment Group held 161,597 shares of Allogene Therapeutics worth $336K as of Q2 2026.
  • Partners Capital Investment Group left its Allogene Therapeutics share count unchanged in Q2 2026.
  • Allogene Therapeutics made up 0.01% of Partners Capital Investment Group's portfolio in Q2 2026, its #157 holding.
  • Partners Capital Investment Group first reported a position in Allogene Therapeutics in Q4 2019 and has held it in 27 quarters since.
  • Partners Capital Investment Group's Allogene Therapeutics position peaked at $6.6M in Q4 2020.
  • 210 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Partners Capital Investment Group's 13F filing for Q2 2026, filed 13 Aug 2026.